Hyperliquid Strategies Inc (PURR) is a digital asset treasury company whose balance sheet is dominated by HYPE token holdings. As of March 31, 2026, total assets were $810.4 million against total liabilities of $66.9 million, producing reported stockholders' equity of $743.5 million. However, under a liquidation lens, the recovery picture diverges sharply from the GAAP book value. The single largest asset is HYPE digital assets at fair value of $689.5 million ($689.0 million noncurrent), which under liquidation would require a haircut reflecting illiquidity, concentrated single-token exposure, and the absence of a deep institutional bid for this size block. Cash and cash equivalents of $113.1 million recover at 100%. The $3.6 million equity method investment in Guidant Bio Therapeutics (40% interest, received in exchange for Sonnet pipeline assets and $1.325 million cash) has effectively zero recovery value given it is a pre-revenue biotech startup. The $3.6 million prepaid/other current assets would recover modestly. On the liability side, current liabilities of $6.4 million (accounts payable $2.6 million, other current liabilities $3.9 million including a $1.0 million deferred purchase price to Guidant and approximately $0.6 million remaining Sonnet warrant settlement obligation) are held at face value. The non-current deferred tax liability of $60.5 million is the most consequential liability item: under liquidation, a wind-up triggering realization of the HYPE position would crystallize this obligation at or near face value, directly reducing equity recovery. The CVR liability (nominal per company assessment) and the advisor warrant obligations (29.8 million warrants outstanding, classified outside liabilities as equity instruments) do not add to the liability stack in liquidation under current accounting. MFFAIS CLV/LLV/OLV of approximately $107 million reflects cash plus thin current asset recovery less current liabilities, and is directionally consistent with a conservative view that strips out HYPE entirely. The key change versus the prior quarter (December 31, 2025): HYPE fair value increased from $327.6 million to $689.0 million, cash declined from $281.9 million to $113.1 million as approximately $160 million was deployed into HYPE purchases, and the deferred tax liability grew from $17.8 million to $60.5 million. The Sonnet asset disposition (APA with Guidant) closed March 31, 2026, replacing biotech pipeline intangibles with a minority equity method stake. The $35.6 million IPR&D write-off was a same-period income statement charge with no residual balance sheet asset. The filing discusses the $169.2 million loss on HYPE contribution commitment (HYPE tokens valued at $580.5 million at commitment vs. $411.3 million at closing) but this is a prior-period economics item now embedded in accumulated deficit of $165.9 million. Subsequent to period-end, the company raised $64.6 million via the Equity Facility and deployed it primarily into additional HYPE purchases, further concentrating the asset base.
▼ Community Notes